ANI Pharmaceuticals Inc Asset Resilience Ratio
ANI Pharmaceuticals Inc asset resilience ratio. ANI Pharmaceuticals Inc (ANIP) has an Asset Resilience Ratio of 0.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ANIP current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ANI Pharmaceuticals Inc (2004–2025)
Asset resilience ratio of ANI Pharmaceuticals Inc from 2004 to 2025. This chart shows how ANI Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ANIP free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down ANI Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ANI Pharmaceuticals Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.13 Million | 0.63% |
| Total Liquid Assets | $9.13 Million | 0.63% |
Asset Resilience Insights
- Limited Liquidity: ANI Pharmaceuticals Inc maintains only 0.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ANI Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare ANI Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
ANI Pharmaceuticals Inc Asset Resilience Ratio by Year (2004–2025)
ANI Pharmaceuticals Inc asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for ANI Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.63% | $9.13 Million | $1.44 Billion | +0.14pp |
| 2024-12-31 | 0.49% | $6.31 Million | $1.28 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $904.42 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $412.14 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $322.86 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $285.26 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $263.71 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $44.50 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $38.77 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $62.38 Million | -- |
| 2008-12-31 | 17.12% | $3.03 Million | $17.68 Million | -30.91pp |
| 2007-12-31 | 48.03% | $15.01 Million | $31.24 Million | +31.06pp |
| 2006-12-31 | 16.97% | $3.80 Million | $22.37 Million | -74.85pp |
| 2005-12-31 | 91.82% | $8.79 Million | $9.57 Million | +1.51pp |
| 2004-12-31 | 90.30% | $16.10 Million | $17.83 Million | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more